□□□□□□/□□□□□□03_Phase III COMBI-v□□

□□□□□□□□□□□□□□Phase III COMBI-v□□

COMBI-v□□ □□□□

□□□□

Image



□□ □ BRAF V600E/K□□

□□ □ BRAF V600E/K□□□□□□□□□□□□□□□□□IIIc□□□□□□□□□IV□□□□□□□□□□□

□□□□□□ □ □□□□□□OS□

□□□□□□ □ □□□□□□□□□PFS□□12□□□□□□□□□□□□□□□□□□□

□□□□ □ □□□□□□□□□log-rank□□□χ2□□□ANCOVA□□□□□□□□□□□□□□□□□□0.05□□□□□□□□□□□□□□□□□QOL□□□□□□

□□5□□□□□□□□□□□□□□□□□□□□□□□□□□

Robert, C. et al□.N. Engl. J. Med. 2015; 372 (1): 30-39□□□□□□□□□
□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□
□□□□□□□□□□□□□□7□□□□□□□□□
Grob, JJ. et al□. Lancet Oncol. 2015; 16 (13): 1389-1398□□□□□□□□□
□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□
□□□□□□□□□□□□□□8□□□□□□□□□
□□□□□□□□III□□□□□MEK116513□□□COMBI-v□□2016□3□28□□□□
CTD2.7.6 MEK116513□□□COMBI-v□□□□<□□□□□□□> □20160216□

□□□□□□□OS□□□□□□□□□□

Image



□□□□□□□□□2018□10□8□
Robert C, et al.: N Engl J Med. 2019: 381□7□: 626-636.
□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□21□□□□□□□□□

□□□□□□□□□□□□□

- □□□□□□□□□□□□□□□□□□□□□□□□□320/350□□91□□□□□□□□□□□□□□□□□342/349□□98□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□163□□47□□□□□98□□28%□□□□81□□23%□□□□□□□□□□□□□□□□□□□□162□□46%□□□□146□□42%□□□□□136□□39%□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□
- □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□131□□37□□□□□□□□□□□□□□□□□122□□35□□49□□□□□□□24□□□□13□□□□□□□□□□□□□□□□□□□□□□□□□33□□□□□□□□□□□21□□□□□□□□□17□□□□□□□

- [illegible]44[illegible]13%[illegible]41[illegible]12%[illegible]12[illegible]10[illegible]7[illegible]5[illegible]4[illegible]
- [illegible]2[illegible]1[illegible]1[illegible]

[illegible]2013[illegible]8[illegible]26[illegible]
[illegible]Ⅲ[illegible]MEK115306[illegible]COMBI-d[illegible]2016[illegible]3[illegible]28[illegible]CTD2.7.6 MEK115306[illegible]COMBI-d[illegible]20160217[illegible]

[illegible]

[illegible]

Source URL: *https://www.loadtest.pro.novartis.com/products/tafmek/mel/clinical_03*